As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

The new menu includes five smoothies “created to assist the millions of Americans currently taking prescription GLP-1 medications" Sabrina Weiss is the Editorial Assistant of PEOPLE's food ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Advertisement Under the Medicaid system ...

PHILADELPHIA — The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with a significant decrease in the risk for early-onset colorectal cancer (EO-CRC) in patients with ...

The company benefits from GLP-1 drug sales and is positioned for high margins and recurring revenues in the growing healthcare market. HIMS achieved positive operating income with 50% revenue ...

Nov 1 (Reuters) - In a practice-changing guideline reversal, medical societies advised, opens new tab on Tuesday that most patients do not need to stop taking GLP-1 diabetes and weight-loss drugs ...

It found that over 12 months, 1.4% of adolescents on GLP-1 drugs had a suicide attempt or ideation, compared with 2.3% who weren’t on the medicines. There was no sign of an increase associated ...